Avidity Biosciences, Inc.
RNA
$71.51
-$0.07-0.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -174.44M | -157.32M | -115.77M | -102.26M | -80.40M |
| Total Depreciation and Amortization | 1.06M | 814.00K | 785.00K | 738.00K | 710.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.73M | 15.01M | 13.40M | 7.81M | 8.07M |
| Change in Net Operating Assets | -516.00K | -58.17M | -23.24M | -6.16M | 6.01M |
| Cash from Operations | -156.17M | -199.67M | -124.83M | -99.87M | -65.62M |
| Capital Expenditure | -712.00K | -3.34M | -3.75M | -3.92M | -1.70M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -587.21M | 188.83M | 160.94M | -60.26M | -480.71M |
| Cash from Investing | -587.93M | 185.49M | 157.19M | -64.17M | -482.41M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 850.37M | 3.77M | 1.94M | 13.72M | 342.46M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Financing | 850.37M | 3.77M | 1.94M | 13.72M | 342.46M |
| Foreign Exchange rate Adjustments | -16.00K | 115.00K | 39.00K | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 106.25M | -10.29M | 34.34M | -150.32M | -205.56M |